{
  "nctId": "NCT05446090",
  "briefTitle": "Asthma: Phenotyping Exacerbations 3",
  "officialTitle": "Asthma: Phenotyping Exacerbations 3",
  "protocolDocument": {
    "nctId": "NCT05446090",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-11-10",
    "uploadDate": "2022-06-01T04:25",
    "size": 1483822,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05446090/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 100,
    "enrollmentType": "ESTIMATED"
  },
  "timeline": {
    "startDate": "2022-05-09",
    "completionDate": "2023-12-31",
    "primaryCompletionDate": "2023-12-31",
    "firstSubmitDate": "2022-05-26",
    "firstPostDate": "2022-07-06"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* The ability to give fully informed consent\n* Male or female aged â‰¥ 18 years of age.\n* Admission with a suspected acute asthma attack.\n* Able (in the investigator's opinion) and willing to comply with clinical investigation requirements.\n\nExclusion Criteria:\n\n* Other clinically significant respiratory diseases including predominant Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis.\n* Any other clinically significant medical disease or uncontrolled concomitant disease that is likely, in the investigator's opinion, to impact the ability to participate in the study or the study results.\n* Pregnant women, lactating women or women who are planning to become pregnant.\n* Investigator determined apparent other cause for admission.\n* Acute COVID infection.\n* Non-English-speaking participants who are unable to comprehend the reasons for the study due to limitations in understanding the English language",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Assessment of cytokine levels in nasal lining fluid at attack and recovery visits",
        "description": "Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.",
        "timeFrame": "14 days"
      },
      {
        "measure": "The measurement of vitamin D levels in the blood on admission to the hospital",
        "description": "vitamin D levels in the blood on admission to the hospital",
        "timeFrame": "baseline"
      },
      {
        "measure": "Assessment of evidence of infection: sputum for bacterial culture and sensitivity (MC&S).",
        "description": "Assessment of evidence of infection: sputum for bacterial culture and sensitivity (MC\\&S).",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of evidence of infection: CRP.",
        "description": "Assessment of evidence of infection: CRP.",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of evidence of infection: Throat swab/nasal lavage for viral PCR.",
        "description": "Assessment of evidence of infection: Throat swab/nasal lavage for viral PCR.",
        "timeFrame": "baseline"
      },
      {
        "measure": "A specific asthma history (polypharmacy, previous asthma attacks, triggers, Personalised Asthma Action Plan) for the assessment of risk factor for attack.",
        "description": "Assessment of risk factor for attack",
        "timeFrame": "baseline"
      },
      {
        "measure": "Assessment of adherence to medications (MARS, prescription records, inhaler technique) for the assessment of behavioural attack traits.",
        "description": "Assessment of behavioural attack traits.",
        "timeFrame": "baseline"
      },
      {
        "measure": "Assessment of airway obstruction at attack and recovery visits using peak expiratory flow rate (PEFR).",
        "description": "Assessment of airway obstruction",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of airway obstruction at attack and recovery visits using spirometry.",
        "description": "Assessment of airway obstruction",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of airway obstruction at attack and recovery visits using Forced Oscillation Technique (FOT).",
        "description": "Assessment of airway obstruction",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of airway obstruction at attack using physician recorded expiratory wheeze",
        "description": "Assessment of airway obstruction",
        "timeFrame": "baseline"
      },
      {
        "measure": "Assessment of airway inflammation at attack and recovery visits using Fractional Exhaled Nitric Oxide (FeNO).",
        "description": "Assessment of airway inflammation",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of airway inflammation at attack and recovery visits using sputum inflammatory cell count.",
        "description": "Assessment of airway inflammation",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of airway inflammation at attack and recovery visits using blood eosinophil count.",
        "description": "Assessment of airway inflammation",
        "timeFrame": "14 days"
      },
      {
        "measure": "Assessment of symptom burden at attack and recovery visits using the Acute AQLQ questionnaire",
        "description": "Assessment of symptom burden",
        "timeFrame": "28 days"
      },
      {
        "measure": "Assessment of Body Mass Index BMI.",
        "description": "Assessment of Body Mass Index BMI.",
        "timeFrame": "baseline"
      },
      {
        "measure": "Assessment of the incidence of upper airway symptoms.",
        "description": "The incidence of upper airway symptoms will be assessed using the Sino-nasal Outcome Test (SNOT).",
        "timeFrame": "baseline"
      },
      {
        "measure": "The assessment of the incidence of Gastroesophageal Reflux Disease.",
        "description": "The assessment of the incidence of Gastroesophageal Reflux Disease using the GERDQ questionnaire.",
        "timeFrame": "baseline"
      },
      {
        "measure": "The assessment of the incidence of vocal cord dysfunction",
        "description": "The assessment of the incidence of vocal cord dysfunction using the Pittsburgh Vocal Cord Dysfunction (VCD) Index.",
        "timeFrame": "baseline"
      },
      {
        "measure": "The assessment of the incidence of dysfunctional breathing",
        "description": "The assessment of the incidence of dysfunctional breathing using the Nijmegen dysfunctional questionnaire.",
        "timeFrame": "baseline"
      },
      {
        "measure": "The assessment of the incidence of anxiety and depression",
        "description": "The assessment of the incidence of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS).",
        "timeFrame": "baseline"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 21,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 21
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:21.727Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}